|Gardiquimod VacciGrade™||Unit size||Cat. code||Docs||Qty||Price|
Imidazoquinoline compound -TLR7 agonist
Gardiquimod™ is an imidazoquinoline compound developed and manufactured by InvivoGen. This imidazoquinoline compound is a guanosine derivative and agonist for TLR7. Gardiquimod™ is an effective adjuvant by activating dendritic cells (DCs) and B cells to induce cytokines optimal for Th1 cell immunity, and antibody production.
Gardiquimod™ VacciGrade™ is suitable for preclinical studies. It is prepared under strict aseptic conditions. It is guaranteed sterile and thoroughly tested for the presence of endotoxins.
Gardiquimod™ VacciGrade™ is for research use only, not for use in humans.
Specificity: Th1 response
Working concentration: 10- 100 μg/mouse
Quality: Sterile, Endotoxin level <5 EU/mg
CAS number: 1020412-43-4
Solubility: 1 mg/ml in physiological water
- Gardiquimod™ VacciGrade™ is a preclinical grade preparation of Gardiquimod™ .
- It is prepared under strict aseptic conditions and is tested for the presence of endotoxins.
- Gardiquimod™ VacciGrade™ is guaranteed sterile and its endotoxin level is <5 EU/mg.
- 5 mg of sterile lyophilized Gardiquimod VacciGrade™
- 10 ml sterile endotoxin-free physiological water (NaCl 0.9%)
Gardiquimod VacciGrade™ is shipped at room temperature
Stored at -20°C.
Lyophilized product is stable for 1 year when properly stored.
Upon resuspension, prepare aliquots of Gardiiquimod VacciGrade™ and store at -20°C.
Resuspended product is stable for 6 months when properly stored. Avoid repeated freeze-thaw cycles.Back to the top
Gardiquimod™ is a imidazoquinoline compound developed and manufactured by InvivoGen.
Similarly to Imiquimod, Gardiquimod™ induces the activation of NF-κB in HEK293 cells expressing human or mouse TLR7.
In vitro models of vaccination indicate that Gardiquimod™ is a strong immunostimulant inducing cytokine production and the generation of dendritic cells .
Experimental models demonstrated that Gardiquimod™ can induce strong cellular responses and has potential as an adjuvant for cancer therapy [2, 3].
Furthermore, Gardiquimod™ can induce mucosal responses that are superior to R848 and comparable to those induced by the established mucosal adjuvant cholera toxin .
1. Ma Y et al., 2007. In vitro vaccination site: a novel test bed for immunopotentiators. J Immunol. 178, S18.
2 Ma F. et al., 2010. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cellular & Molecular Immunology 7, 381-388.
3. Cho HI & Celis E., 2009. Optimized Peptide Vaccines Eliciting Extensive CD8 T-Cell Responses with Therapeutic Antitumor Effects. Cancer Res. 69(23):9012-9.
4. Velasquez LS. et al., 2010. An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles. Clin Vaccine Immunol. 17(12):1850-8.